Literature DB >> 10374405

CT-guided stereotactic biopsy of deep brain lesions: report of 310 cases.

X Yu1, Z Liu, Z Tian, S Li, H Huang, Q Zhao, Y Xu, Y Cui, X Yu1.   

Abstract

OBJECTIVE: To evaluate the accuracy of CT-guided stereotactic biopsy in making correct pathological diagnosis and choosing corresponding management of brain tumors.
METHODS: From 1991 to 1995, CT-guided stereotactic biopsy was performed in 310 patients with intracerebral lesions which were deep-seated or located in certain main functional areas. The patients were 198 men and 112 women. Their ages ranged from 4.5 to 70 years (average: 39.3 years). The lesions were located in the deep cerebrum (74 patients), the sellar area (62), the basal ganglion (51), the posterior part of the third ventricle (38), other intraventricleular area (21), the cerebellum (17) and the brain stem (9), and intracranial multiple lesions were found in 38 patients.
RESULTS: Brain tumors were diagnosed pathologically in 266 patients (85.8%); inflammatory process in 25 (8.1%), other lesions in 8 (2.6%) and uncertain cases were 11 (3.6%). The overall positive rate of biopsy was 96.4% and the positive rate for brain tumor was 85.8%. Intracranial hematomas after biopsy were found in 5 patients (1.6%). There were no deaths induced by the biopsy or other serious complications.
CONCLUSIONS: The results suggest that CT-guided stereotactic biopsy is a reliable method for histopathological diagnosis of brain tumors and it is also of great help in selecting appropriate management.

Entities:  

Mesh:

Year:  1998        PMID: 10374405

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  3 in total

1.  Stereotactic Biopsy for Brainstem Lesions: A Meta-analysis with Noncomparative Binary Data.

Authors:  Lin He; Dongjie He; Yuhong Qi; Jiejing Zhou; Canliang Yuan; Hao Chang; Qiming Wang; Gaiyan Li; Qiuju Shao
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

Review 2.  Primary central nervous system lymphomas.

Authors:  L M DeAngelis
Journal:  Curr Treat Options Oncol       Date:  2001-08

3.  Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma.

Authors:  Defeng Zhao; Liren Qian; Jianliang Shen; Xiaopeng Liu; Ke Mei; Jian Cen; Yaming Wang; Congyong Li; Yuanyuan Ma
Journal:  J Cell Mol Med       Date:  2014-03-13       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.